Abstract
Cytosine arabinoside (Ara-C) is one of the most important chemotherapy drugs in curing acute leukemia (AL), comprised in most protocols of combined chemotherapy at present. Deoxycytidine kinase (DCK) is rate-limiting enzyme in the metabolism process of Ara-C in vivo. The expression of DCK gene, as well as the function of DCK has a remarkable impact on curative effect of AL chemotherapy. In this article, we review the influences of DCK gene single nucleotide polymorphism (SNP), expression of DCK gene mRNA and DCK protein phosphorylation on the structure and function of DCK. Key words: Cytarabine; Deoxycytidine kinase; Leukemia
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
